Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
Key facts
- Where
- Boras, Falun, Goteborg, Halmstad, Helsingborg, Huddinge, Jonkoping, Linkoping, Lund, Orebro, Trollhattan, Umea, Uppsala és Varberg, SvédországSee the 14 sites
- Phase
- 2. fázis
Where in Svédország
- Soedra Aelvsborg Hospital Vaestra GoetalandsregionenBoras, SvédországTaking people
- Region DalarnaFalun, SvédországTaking people
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SvédországTaking people
- Region HallandHalmstad, SvédországTaking people
- Region Skane Helsingborg HospitalHelsingborg, SvédországTaking people
- Karolinska University HospitalHuddinge, SvédországTaking people
- Region Joenkoepings LaenJonkoping, SvédországTaking people
- Region OestergoetlandLinkoping, SvédországTaking people
- Region Skane Skanes UniversitetssjukhusLund, SvédországTaking people
- Region Oerebro LaenOrebro, SvédországTaking people
- NU Hospital Group-Vaestra GoetalandsregionenTrollhattan, SvédországTaking people
- Region VaesterbottenUmea, SvédországTaking people
- Uppsala University HospitalUppsala, SvédországTaking people
- Region HallandVarberg, SvédországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vaestra Goetalandsregionen
- Trial code
- EU 2025-524022-18-00
- Record updated
- 2026. február 16.
- Original description
The primary objective of this trial is to assess the duration of remission and therapy free time after stopping BCMA-CD3 bispecific antibody therapy in patients with major M-spike response.Read full original descriptionShow less
A multicenter prospective trial estimating the persistence of remission after stopping BCMA-CD3 bispecific antibody in multiple myeloma patients with major M-spike response by use MaldiTOF-based high sensitivity monitoring
The primary objective of this trial is to assess the duration of remission and therapy free time after stopping BCMA-CD3 bispecific antibody therapy in patients with major M-spike response.
Inclusion: The subject has given their written consent to participate in the trial; Multiple myeloma diagnosis according to IMWG criteria; On-going BCMA-CD3 bispecific antibody therapy; Biochemical complete response (CR), with unmeasurable M-spike and normal or unmeasurable free light chains on local analysis on ongoing BCMA-CD3 bispecific antibody therapy; Measurable disease before BCMA-CD3 bispecific antibody treatment initiation by local analysis (defined as M-spike >5g/L or involved FLC >100mg/L); Available baseline data from MM diagnosis; Available data on earlier MM treatments; 18 years or older.
Exclusion: Severe concomitant disease with life expectancy of < 6 month; Subjects who are unable to adhere to the monitoring of the disease according to protocol; Subjects without ability to give informed consent; Multiple myeloma of IgD or IgE type.